z-logo
Premium
PD‐1 inhibition in congenital pigment synthesizing metastatic melanoma
Author(s) -
Weyand Angela C.,
Mody Rajen J.,
Rabah Raja M.,
Opipari Valerie P.
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26702
Subject(s) - medicine , nivolumab , exome sequencing , melanoma , cancer research , mutation , somatic cell , cancer , oncology , genetics , immunotherapy , biology , gene
A newborn female child was born with a congenital pigment synthesizing melanoma of the scalp. Further workup revealed metastatic disease within the liver, lungs, and left tibia. Whole exome sequencing was performed on multiple samples that revealed one somatic mutation, lysine methyltransferase 2C (KMT2C), at low allelic frequency but no v‐Raf murine sarcoma viral oncogene homolog B (BRAF), NF‐1 mutation. Programmed death ligand 1 was moderately expressed. Treatment was initiated with the programmed cell death protein 1 inhibitor nivolumab. The patient tolerated this treatment well with minimal toxicity. She is now over a year out from initial diagnosis, continuing on nivolumab, with stable disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here